The firm said its remaining employees will focus on developing the pol theta inhibitor RP-3467 and the PLK4 inhibitor RP-1664.

The company said the move demonstrates the board of directors' confidence in the potential of its PARP1/2 inhibitor in ovarian cancer.

ABI-201 is undergoing IND-enabling studies and uses the same capsid as the firm's clinical-stage gene therapy candidate for wet AMD.

The firm said it will rely on academic partnerships and contract manufacturers to support its cell therapy clinical trials.

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.

Krystal said it is on track to launch Vyjuvek in Germany in the middle of the year and in France later in 2025.

The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.